BR112018006689A2 - terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle - Google Patents

terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle

Info

Publication number
BR112018006689A2
BR112018006689A2 BR112018006689A BR112018006689A BR112018006689A2 BR 112018006689 A2 BR112018006689 A2 BR 112018006689A2 BR 112018006689 A BR112018006689 A BR 112018006689A BR 112018006689 A BR112018006689 A BR 112018006689A BR 112018006689 A2 BR112018006689 A2 BR 112018006689A2
Authority
BR
Brazil
Prior art keywords
bromodomain inhibitor
control point
combination therapy
point block
inhibitor combination
Prior art date
Application number
BR112018006689A
Other languages
English (en)
Inventor
Shortt Jake
E Bradner James
Wayne Johnston Ricky
John Hogg Simon
Original Assignee
Dana Farber Cancer Inst Inc
Peter Maccallum Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Peter Maccallum Cancer Inst filed Critical Dana Farber Cancer Inst Inc
Publication of BR112018006689A2 publication Critical patent/BR112018006689A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

a presente divulgação provê a terapia de combinação de um inibidor de bromodomínio e um modulador imunológico (por exemplo, um inibidor do ponto de controle imunológico). a combinação do inibidor de bromodomínio e do modulador imunológico pode ser útil no tratamento ou prevenção de câncer em um indivíduo. em certas modalidades, o sujeito possui um sistema imunológico intacto. a combinação do inibidor de bromodomínio e do modulador imunológico deve ser sinérgica.
BR112018006689A 2015-10-02 2016-09-30 terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle BR112018006689A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236280P 2015-10-02 2015-10-02
PCT/US2016/054924 WO2017059319A2 (en) 2015-10-02 2016-09-30 Combination therapy of bromodomain inhibitors and checkpoint blockade

Publications (1)

Publication Number Publication Date
BR112018006689A2 true BR112018006689A2 (pt) 2018-10-09

Family

ID=57137298

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006689A BR112018006689A2 (pt) 2015-10-02 2016-09-30 terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle

Country Status (16)

Country Link
US (1) US20190192532A1 (pt)
EP (1) EP3355922A2 (pt)
JP (1) JP2018530554A (pt)
KR (1) KR20180081507A (pt)
CN (1) CN108289957A (pt)
AR (1) AR107500A1 (pt)
AU (1) AU2016331190A1 (pt)
BR (1) BR112018006689A2 (pt)
CA (1) CA2999523A1 (pt)
CL (1) CL2018000853A1 (pt)
HK (1) HK1256269A1 (pt)
IL (1) IL258212A (pt)
MA (1) MA43037A (pt)
MX (1) MX2018003824A (pt)
PE (1) PE20181068A1 (pt)
WO (1) WO2017059319A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608316T3 (es) * 2005-06-08 2017-04-07 Dana-Farber Cancer Institute, Inc. Métodos y composiciones para el tratamiento del cáncer e infecciones persistentes mediante la inhibición de la ruta de la muerte celular 1 (PD-1) programada
WO2009139930A2 (en) 2008-05-16 2009-11-19 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
SG193831A1 (en) 2008-08-28 2013-10-30 Taiga Biotechnologies Inc Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
MX2012013255A (es) 2010-05-14 2013-02-27 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
PE20171042A1 (es) 2014-10-27 2017-07-19 Tensha Therapeutics Inc Inhibidores del bromodominio
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
EP3578555B1 (en) * 2018-01-16 2022-09-21 Shenzhen TargetRx, Inc. Diphenylaminopyrimidine compound for inhibiting kinase activity
WO2020051571A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN109666723B (zh) * 2019-01-22 2022-04-15 南通大学 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用
EP3969041A4 (en) * 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
US20230093080A1 (en) * 2019-07-15 2023-03-23 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20230053152A1 (en) * 2019-11-26 2023-02-16 Benobio Co., Ltd. Novel Quercetin Redox Derivative And Use Thereof As BET Inhibitor
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
KR20230057341A (ko) 2020-07-02 2023-04-28 인사이트 코포레이션 Jak2 v617f 억제제로서 삼환계 우레아 화합물
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037423B1 (en) * 2009-11-05 2017-09-20 Glaxosmithkline LLC Novel benzodiazepine compound
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
MX2012013255A (es) * 2010-05-14 2013-02-27 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
EP2571875A4 (en) * 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
WO2012075456A1 (en) * 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
CN105189514A (zh) * 2013-02-22 2015-12-23 拜耳医药股份有限公司 作为bet-蛋白抑制剂用于治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓
EP2958923A1 (de) * 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituierte pyrrolo- und pyrazolo-diazepine
RU2015144185A (ru) * 2013-03-15 2017-04-26 Дженентек, Инк. Лечение заболеваний, опосредованных тh2, путем ингибирования бромодоменов
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015018521A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
RU2016118008A (ru) * 2013-10-11 2017-11-16 Дженентек, Инк. Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака
LT3087071T (lt) * 2013-12-24 2018-11-12 Bristol-Myers Squibb Company Tricikliniai junginiai kaip priešvėžiniai agentai

Also Published As

Publication number Publication date
EP3355922A2 (en) 2018-08-08
MA43037A (fr) 2018-08-08
WO2017059319A2 (en) 2017-04-06
IL258212A (en) 2018-05-31
KR20180081507A (ko) 2018-07-16
CA2999523A1 (en) 2017-04-06
CN108289957A (zh) 2018-07-17
AU2016331190A1 (en) 2018-04-12
US20190192532A1 (en) 2019-06-27
WO2017059319A3 (en) 2017-10-12
JP2018530554A (ja) 2018-10-18
CL2018000853A1 (es) 2018-08-31
PE20181068A1 (es) 2018-07-04
MX2018003824A (es) 2019-04-01
AR107500A1 (es) 2018-05-09
HK1256269A1 (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
BR112018006689A2 (pt) terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
MX2022003895A (es) Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2018015352A (es) Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
MX2018015770A (es) Variantes de virus adenoasociados y metodos para usarlos.
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112016015399A2 (pt) método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico
BR112017019036A2 (pt) comunicações de usuário com um comerciante através de um sistema de rede social
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017001162A2 (pt) métodos para tratar paramixovírus
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112018067330A2 (pt) método para o tratamento de paciente com carga tumoral
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
CA3060516A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
BR112018075135A2 (pt) combinações farmacêuticas para tratar câncer
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.